FENNEC PHARMACEUTICALS INC. (FENC) Debt Components
- 2025-09-30: Long-term DebtUSD $19.38M; Long-Term Debt, Maturity, Year ThreeUSD $18.21M; Long-Term Debt, Maturity, Year FourUSD (m); Long-term Debt, GrossUSD $18.21M.
- 2025-06-30: Long-term DebtUSD $19.36M; Long-Term Debt, Maturity, Year ThreeUSD $18.21M; Long-Term Debt, Maturity, Year FourUSD (m); Long-term Debt, GrossUSD $18.21M.
- 2025-03-31: Long-term DebtUSD $19.35M; Long-Term Debt, Maturity, Year ThreeUSD $18.21M; Long-Term Debt, Maturity, Year FourUSD (m); Long-term Debt, GrossUSD $18.21M.
- 2024-12-31: Long-term DebtUSD (m); Long-Term Debt, Maturity, Year ThreeUSD (m); Long-Term Debt, Maturity, Year FourUSD (m); Long-term Debt, GrossUSD $18.21M.
FENNEC PHARMACEUTICALS INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount USD | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-Term Debt, Maturity, Year Five USD | Line of Credit Facility, Maximum Borrowing Capacity USD |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | $19.38M | $18.21M | (m) | $18.21M | $100.00K | (m) | (m) | (m) | (m) |
| 2025-06-30 | $19.36M | $18.21M | (m) | $18.21M | $113.00K | (m) | (m) | (m) | (m) |
| 2025-03-31 | $19.35M | $18.21M | (m) | $18.21M | $126.00K | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | $18.21M | $139.00K | (m) | (m) | (m) | (m) |
| 2024-12-31 | $19.34M | $18.21M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $32.10M | (m) | $30.00M | $30.00M | $227.00K | (m) | (m) | (m) | (m) |
| 2024-06-30 | $31.77M | (m) | $30.00M | $30.00M | $247.00K | (m) | (m) | (m) | (m) |
| 2024-03-31 | $31.35M | (m) | $30.00M | $30.00M | $268.00K | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | $30.00M | $288.00K | (m) | (m) | (m) | (m) |
| 2023-12-31 | $30.93M | (m) | $30.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $25.64M | (m) | (m) | $25.00M | $298.00K | (m) | (m) | $25.00M | (m) |
| 2023-06-30 | $25.39M | (m) | (m) | $25.00M | $321.00K | (m) | (m) | $25.00M | (m) |
| 2023-03-31 | $25.14M | (m) | (m) | $25.00M | $341.00K | (m) | (m) | $25.00M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $25.00M | $361.00K | (m) | (m) | (m) | (m) |
| 2022-12-31 | $24.90M | (m) | (m) | (m) | (m) | (m) | (m) | $25.00M | (m) |
| 2022-09-30 | $24.69M | (m) | (m) | $25.00M | $312.00K | (m) | $25.00M | $25.00M | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | $10.00K | $1.00M | $4.00M | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | $11.00K | $500.00K | $4.50M | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $5.00M | $12.00K | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | $5.00M | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | $5.00M | $13.00K | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | $5.00M | $14.00K | (m) | (m) | (m) | (m) |
| 2019-02-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $18.00M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |